---
title: "editorial uspstf recommendations"
year: 2025
month: 02
journal: "American Family Physician"
volume: "109-110"
issue: "02"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2025-02-editorial-uspstf-recommendations.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial uspstf recommendations

Editorials


Evidence Considerations for Recent
USPSTF Recommendations
Mark H. Ebell, MD, MS, and Kenneth W. Lin, MD, MPH




T     he US Preventive Services Task Force (USPSTF) recently
      celebrated its 40th anniversary. The goal of the USPSTF is
to make evidence-based recommendations regarding screening
                                                                            Modeling has an important role in evaluating benefits and
                                                                         harms, different ages to begin and stop screening, and differ-
                                                                         ent screening intervals in the absence of RCTs.13 However, it
and prevention that improve health and prolong life;​cost has            has become clear that modeling has limitations in accurately
not traditionally been considered, only potential benefits and           projecting health outcomes from a screening program. For
harms. The USPSTF has been lauded as a model for guideline               example, the USPSTF modeling study for colorectal cancer
development due to its rigorous evidence-based processes.1 Each          screening estimates that for every 1,000 people 50 to 74 years
of the 88 recommendations is based on an independent sys-                of age undergoing colonoscopy every 10 years, 27 colorectal
tematic review and an assessment and discussion of outcomes              cancer deaths are averted (a 2.7% reduction), at the cost of
and quality of evidence by USPSTF members, with input from               14 serious complications.7 But a subsequently published RCT
external reviewers and the public. Each final recommendation             comparing colonoscopy with no screening in patients 55 to 64
statement must then be ratified by a vote.                               years of age found that even with the most optimistic analy-
   For some preventive services, the USPSTF determines that              sis, the reduction in mortality was only 0.15% after 10 years.8
a recommendation cannot be made due to insufficient evi-                 Even with a longer timeline, it is difficult to imagine that the
dence. Most graded recommendations are based on direct                   mortality reduction in the trial participants would approach
evidence from randomized controlled trials (RCTs) compar-                2.7%. The USPSTF acknowledges the limitations of modeling,
ing the benefits and harms of a screening test or preventive             and it is hoped that discrepancies like this will be studied to
service with no intervention or placebo. Examples include                improve future models.13
all recommended cancer screening tests, aspirin for primary                 Regarding breast cancer screening for women 40 to 49 years
prevention, and medications to reduce the risk of breast can-            of age, the USPSTF recently updated the recommendation
cer. For some conditions, such as HIV infection, no RCTs                 from shared decision-making based on individual risk and
of screening have evaluated patient-oriented outcomes.2 In               values to screening for all women beginning at age 40.3 This
this case, the USPSTF has recommended screening based                    change occurred despite no new RCTs on the benefits and
on a causal chain:​the screening tests are accurate, and treat-          harms of different starting ages and no substantial change in
ments reduce the risk of death, AIDS-related illness, and                modeling outputs.14 In addition, it is in the context that up to
transmission.                                                            4 in 10 women in the United States in this age group prefer to
   However, some recent recommendations have raised con-                 delay screening after being informed of the benefits and harms,
cerns about the consistency of the USPSTF’s processes and                and that experiencing a false-positive mammogram result is
how they are applied (Table 13-12). Potential problems include           associated with a reduction in the likelihood that a patient will
an overreliance on modeling projections, recommendations that            return for subsequent mammograms.15,16
have changed in the apparent absence of new evidence, and                   A stated goal of the USPSTF is a desire to improve equity,
recommendations that appear to be inconsistent with the best             and although Black women already have higher screening rates
available evidence from clinical trials.                                 than White women or women of Asian descent, they also have
                                                                         higher mortality rates for breast cancer.17 In this case, enhanc-
                                                                         ing equity may come with a higher burden or harm for some
   Mark H. Ebell, MD, MS, Michigan State University Col-                 women, with uncertain additional benefit. Such trade-offs
   lege of Human Medicine, East Lansing                                  should be discussed more explicitly.
                                                                            In some cases, updated recommendations do not align with
   Kenneth W. Lin, MD, MPH, Lancaster General Hospital
                                                                         data from existing or newly published RCTs. For example, a
   Family Medicine Residency, Lancaster, Pennsylvania
                                                                         large study on lung cancer screening in the Netherlands found
   Author disclosure:​No relevant financial relationships.               outcomes that were equivalent to or better than those of the
   Address correspondence to Kenneth W. Lin, MD, MPH, at                 comparable trial in the United States. The study was also able
   Kenneth.Lin@​georgetown.edu.                                          to gradually lengthen the testing interval from 1 to 2.5 years,
                                                                         reducing cost and harm without compromising benefit.5 Based

              Downloaded from the American Family Physician website at www.aafp.org/afp. Copyright © 2025 American Acad-
110 American Family Physician	                                                                            Volume 111, Number 2 • February 2025
               emy of Family Physicians. For the private, noncommercial use of one individual user of the website. All other rights
                           reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                                                                             EDITORIALS



  TABLE 1

  Selected Recent USPSTF Recommendations

                                Change from previous
  Recommendation                recommendation                      USPSTF rationale          Problems with rationale

  Screening for breast          Lowered age to begin routine        Improve health equity     No new RCTs addressing age to start
  cancer (2024, B grade)3       screening mammography                                         screening, no substantial change in mod-
                                from 50 to 40 years                                           eling outputs, and may disregard patient
                                                                                              preferences

  Screening for lung can-       Continued to endorse annual         Uncertain                 Large RCT in the Netherlands demon-
  cer (2021, B grade)4          low-dose computed tomog-                                      strated that biennial screening offers
                                raphy screening for high-risk                                 equivalent benefit with lower cost and
                                patients                                                      harms5

  Screening for colorec-        Assumed 2.7% mortality              No published RCTs         Subsequently, an RCT found much
  tal cancer (2021, grade       reduction from colonoscopy          of screening colo-        smaller benefit of screening colonoscopy
  varies depending on           in adults 50 to 74 years of age     noscopy at time of        in best case (0.15% mortality reduction)8
  patient age)   6
                                based on modeling study    7
                                                                    recommendation

  Screening for anxiety         Recommended routine                 Screening tests are       Two adequately powered primary care
  disorders in adults           screening                           accurate, and treat-      RCTs with a total of 918 patients found
  (2023, B grade)9                                                  ment is effective         no benefit of screening10

  Screening for unhealthy       Recommended routine                 Screening tests           Lack of evidence that psychosocial inter-
  drug use in adults            screening                           are accurate, and         ventions and pharmacotherapy reduce
  (2020, B grade)11                                                 treatment improves        drug use or its consequences in patients
                                                                    outcomes in treatment-    with unhealthy drug use identified
                                                                    seeking patients          through screening12

  RCT = randomized controlled trial;​USPSTF = US Preventive Services Task Force.

  Information from references 3-12.




on updated modeling, the USPSTF statement a year later con-               drug use and that interventions in treatment-seeking popula-
tinued to recommend annual screening.4 We suggest that, in                tions improved health outcomes.11 However, there are import-
the face of new evidence and the opportunity to reduce harms,             ant differences between patients with substance use disorders
burden, and cost by safely lengthening intervals, evidence from           identified through screening vs those seeking treatment.19 Nota-
both new trials and modeling be used. For example, the recom-             bly, the USPSTF’s evidence report concluded that although
mendation could explicitly incorporate the new trial evidence             pharmacotherapy and psychosocial interventions effectively
and state that intervals can safely be lengthened over time.              improve drug use outcomes, evidence of effectiveness is pri-
   Another example is the 2023 recommendation to screen for               marily derived from trials conducted in treatment-seeking pop-
anxiety disorders in primary care settings.9 The recommen-                ulations.12 A cluster RCT published after the recommendation
dation rests on the indirect evidence that screening tests are            statement was released found that screening for opioid use dis-
accurate and treatment is effective. However, two adequately              order in diverse primary care settings in the United States did
powered primary care RCTs with a total of 918 patients                    not increase the rate of diagnosis.20 We hope that this new
found no benefit to screening.10 In this case, direct evidence            evidence is used to update the recommendation to better reflect
was outweighed by indirect evidence, a break with previous                the lack of evidence in screened populations.
USPSTF methods. Potential harms of anxiety screening include                 Primary care physicians have come to trust and rely on
increased time and documentation burdens and adverse effects              USPSTF recommendations in clinical practice, and its A and
of unnecessary medications.18                                             B grade assessments have been linked to mandatory private
   Similarly, the 2020 recommendation to routinely screen                 insurance coverage without cost-sharing since 2010.21 To justify
adults for unhealthy drug use relied on a causal chain showing            the extra time and effort associated with implementing new or
that screening questions identified individuals with unhealthy            expanded screening recommendations, clinicians must have

February 2025 • Volume 111, Number 2                                                                        American Family Physician 111
confidence in the reliability of USPSTF assessments regardless             9. Barry MJ, Nicholson WK, Silverstein M, et al. Screening for
                                                                              anxiety disorders in adults:​US Preventive Services Task Force
of the task force’s membership at any point in time. We hope                  recommendation statement. JAMA. 2023;​329(24):​2163-2170.
that this commentary sheds light on why the recommendations               10. O’Connor E, Henninger M, Perdue LA, et al. Screening for Depression,
of the American Academy of Family Physicians occasionally                     Anxiety, and Suicide Risk in Adults:​A Systematic Evidence Review for
differ from those of the USPSTF22 and encourages current                      the U.S. Preventive Services Task Force. Evidence Synthesis No. 223.
                                                                              Agency for Healthcare Research and Quality;​2022.
and future task force members to continue to improve their
                                                                          11. Krist AH, Davidson KW, Mangione CM, et al. Screening for unhealthy
methods for assessing the benefits and harms of clinical pre-                 drug use:​US Preventive Services Task Force recommendation
ventive services.                                                             statement. JAMA. 2020;​323(22):​2301-2309.
  Sir Muir Gray, a preventive medicine expert in the United               12. Patnode CD, Perdue LA, Rushkin M, et al. Screening for Unhealthy
Kingdom, stated that “All screening programmes do harm:​                      Drug Use in Primary Care in Adolescents and Adults, Including
some do good as well, and, of these, some do more good than                   Pregnant Persons:​Updated Systematic Review for the U.S. Preventive
                                                                              Services Task Force. Evidence Synthesis No. 186. Agency for
harm at reasonable cost.” The first task of any public health                 Healthcare Research and Quality;​2020.
service is to identify beneficial programs by appraising the              13. Owens DK, Whitlock EP, Henderson J, et al. Use of decision models
evidence.23                                                                   in the development of evidence-based clinical preventive services
                                                                              recommendations:​methods of the US Preventive Services Task Force.
                                                                              Ann Intern Med. 2016;​165(7):​501-508.
Editor’s Note:​Dr. Ebell was a member of the USPSTF from 2012             14. Harris RP. The new proposed US Preventive Services Task Force
to 2015 and a consultant to the USPSTF from 2016 to 2020. Dr.                 recommendation on breast cancer screening for women in their 40s:​
                                                                              should the message change? Ann Intern Med. 2024 ;​177(3):​389-392.
Lin was a medical officer at the Agency for Healthcare Research
                                                                          15. Scherer LD, Lewis CL, McCaffery K, et al. Mammography screening
and Quality supporting the USPSTF from 2006 to 2010. Both
                                                                              preferences among screening-eligible women in their 40s:​a national
are members of the AAFP Science Advisory Panel and deputy                     US survey. Ann Intern Med. 2024;​177(8):​1069-1077.
editors for AFP.                                                          16. Miglioretti DL, Abraham L, Sprague BL, et al. Association between
                                                                              false-positive results and return to screening mammography in the
REFERENCES                                                                    breast cancer surveillance consortium cohort. Ann Intern Med. 2024;​
1. Graham R, Mancher M, Miller Wolman D, et al. Clinical Practice             177(10)1297-1307.
   Guidelines We Can Trust. National Academies Press;​2011.               17. Susan G. Komen. How do breast cancer screening rates compare
2. Chou R, Dana T, Grusing S, et al. Screening for HIV infection in           among different groups in the U.S.? Updated October 4, 2024.
   asymptomatic, nonpregnant adolescents and adults:​updated                  Accessed January 8, 2025. https://​w ww.komen.org/breast-cancer/
   evidence report and systematic review for the US Preventive Services       screening/screening-disparities/
   Task Force. JAMA. 2019;​321(23):​2337-2348.                            18. Thombs BD, Markham S, Rice DB, et al. Anxiety screening is unlikely
3. Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast          to improve mental health outcomes. Am Fam Physician. 2024;​109(5):​
   cancer:​US Preventive Services Task Force recommendation                   391-392.
   statement. JAMA. 2024;​331(22):​1918-1930.                             19. Coles S, Vosooney A. Evidence lacking to support universal unhealthy
4. Krist AH, Davidson KW, Mangione CM, et al. Screening for lung              drug use screening. Am Fam Physician. 2021;​103(2):​72-73.
   cancer:​US Preventive Services Task Force recommendation               20. Fortney JC, Ratzliff AD, Blanchard BE, et al. Does screening for opioid
   statement. JAMA. 2021;​325(10):​962-970.                                   use disorder in primary care increase the percentage of patients with
5. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-           a new diagnosis? Ann Intern Med. 2023;​176(10):​1431-1433.
   cancer mortality with volume CT screening in a randomized trial.       21. Siu AL, Bibbins-Domingo K, Grossman D. Evidence-based clinical
   N Engl J Med. 2020;​382(6):​503-513.                                       prevention in the era of the Patient Protection and Affordable Care
6. Davidson KW, Barry MJ, Mangione CM. Screening for colorectal               Act:​the role of the US Preventive Services Task Force. JAMA. 2015;​
   cancer:​US Preventive Services Task Force recommendation                   314(19):​2021-2022.
   statement. JAMA. 2021;​325(19):​1965-1977.                             22. American Academy of Family Physicians. AAFP clinical preventive
7. Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal cancer               services recommendations. Accessed July 26, 2024. https://​w ww.
   screening:​an updated modeling study for the US Preventive Services        aafp.org/family-physician/patient-care/clinical-recommendations/
   Task Force. JAMA. 2021;​325(19):​1998-2011.                                aafp-cps.html

8. Bretthauer M, Løberg M, Wieszczy P, et al.;​NordICC Study Group.       23. Gray JAM, Patnick J, Blanks RG. Maximising benefit and minimising
   Effects of colonoscopy screening on risks of colorectal cancer and         harm of screening. BMJ. 2008;​336(7642):​4 80-483. ■
   related death. N Engl J Med. 2022;​387(17):​1547-1556.




112 American Family Physician	                                                                            Volume 111, Number 2 • February 2025
